# GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

> **NCT02575404** · PHASE1 · COMPLETED · sponsor: **Providence Health & Services** · enrollment: 36 (actual)

## Conditions studied

- Melanoma
- Non-Small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** GR-MD-02
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02575404
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-16
- **Primary completion:** 2021-01-12
- **Final completion:** 2022-10-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02575404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02575404, "GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02575404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*